Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial

NCT02370550 Phase 4 UNKNOWN

The purpose of this large multicenter, randomized, double-blinded, controlled clinical study is to investigate the efficacy and safety of Cyclosporin A for primary Sjogren's syndrome associated pneumonitis(pSS-IP), which has important implications for the establishment of standardized diagnosis and treatment of pSS-IP.

Details

Lead sponsor	Peking University People's Hospital
Phase	Phase 4
Status	UNKNOWN
Enrolment	240
Start date	2015-03
Completion	2021-12

Conditions

• Sjogren's Syndrome

Interventions

• Cyclosporin A
• Prednisone
• Placebo
• Calcium carbonate D

Primary outcomes

• The forced vital capacity (FVC) — the 52 weeks
  The FVC is expressed as percent of expected values corrected baseline level.

Countries

China